New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

Diabetic retinopathy and diabetic macular edema (DME) are two of the most common vision conditions related to diabetes. They affect about 1 in 4 people with type 1 and type 2 diabetes.

Regarding diabetic retinopathy’s prevalence, , there are 40 million Americans who have diabetes, and about 60% of them of them will go on to get diabetic eye disease.

However, left untreated, diabetic retinopathy will steadily get worse over time and start to affect your vision. Treatment can help prevent, delay, and reduce vision loss.

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.

THE Georgetown Public Hospital Corporation (GPHC) has been promoting vision care through early screenings and tests at its eye clinic and the Vision Centre.

Robert Wong, MD: Diabetic retinopathy is a small-vessel ischemic disease. When the blood sugars are elevated, it can affect the blood vessels anywhere in your body. It can affect your heart, your ...